Pfizer will eliminate 5 to 8 percent of its global research staff this year, totaling about 800 people, according to a spokesperson for the company. Pfizer began one-on-one conversations today with colleagues getting the boot, with the majority of lay-offs happening in the next several months, company spokesperson Christopher Loder told The Scientist. Loder declined to provide details on which research divisions will be hit the hardest but emphasized that Pfizer is honing its research staff to six major areas of disease research: oncology, Alzheimer's, schizophrenia, pain, diabetes, and inflammation. "We do not make these decisions lightly," he said. "We are aware that this decision will affect a of number people, colleagues, and their family. We are committed to supporting our colleagues through this transition." Pfizer suffered last year from slumping sales of its blockbuster cholesterol drug Lipitor, thanks to the availability of a generic version. "This is probably...
The New York Times
Interested in reading more?
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?